Physician profile
Willus Mark Horne
NPI 1417961012
$5,389.06
in general payments reported to CMS, 2019-2025
34 companies · $481 in 2025
The $481 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $976 · 2020: $610 · 2021: $655 · 2022: $883 · 2023: $1,324 · 2024: $460 · 2025: $481.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289 · Consulting Fee: $870 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.01 |
| Consulting Fee | $870.00 |
| Education | $105.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,789.53 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbott Laboratories | $472.46 | 2021-2025 | Freestyle Libre |
| Merck Sharp & Dohme LLC | $388.69 | 2019-2023 | Verquvo, Steglatro, Segluromet |
| Boehringer Ingelheim Pharmaceuticals, INC. | $302.23 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $292.99 | 2019-2025 | Xarelto, Spravato |
| Astrazeneca Pharmaceuticals Lp | $279.77 | 2019-2022 | |
| Lilly USA, LLC | $202.41 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Astellas Pharma US INC | $181.03 | 2019-2022 | |
| Pfizer INC. | $175.26 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $155.06 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $141.36 | 2019-2023 | Eliquis |
| Amgen INC. | $131.46 | 2019-2024 | Repatha, Otezla, Evenity |
| Sanofi-Aventis U.S. LLC | $96.39 | 2019 | |
| Insulet Corporation | $89.26 | 2021-2025 | Omnipod |
| Inspire Medical Systems, INC. | $85.86 | 2024-2025 | Inspire |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Global Blood Therapeutics, INC. | $67.07 | 2020-2021 | |
| Abbvie INC. | $64.52 | 2019-2024 | |
| Glaxosmithkline, LLC. | $57.12 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $48.88 | 2019 | |
| Tandem Diabetes Care, INC. | $44.48 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $35.06 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.75 | 2019-2021 | |
| Biogen, INC. | $30.60 | 2021 | |
| Seqirus USA INC | $29.73 | 2019 | |
| Amarin Pharma, INC. | $26.30 | 2019-2020 | |
| Valeritas, INC. | $25.03 | 2019 | |
| Inari Medical, INC. | $21.84 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Averitas Pharma INC. | $21.48 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $21.35 | 2021 | |
| Strongbridge US INC. | $17.73 | 2019 | |
| Exact Sciences Corporation | $17.57 | 2024 | Cologuard Collection Kit |
| Sequel Med Tech, LLC | $15.89 | 2025 | Twiist |
| Medtronic, INC. | $15.15 | 2022 | |
| Nabriva Therapeutics, Plc | $12.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Willus Horne listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.